Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q1 2018 Earnings Presentation
20 slides from Bactiguard Holding Ab's earnings presentation, May 8, 2018
Slide 1: Bactiguard Q1 presentation
1 Bactiguard Q1 presentation 8 May, 2018
Slide 2: Highlights in Q1 and early Q2 2018
2 Highlights in Q1 and early Q2 2018 ✓ Revenues of MSEK 33.0 (41.0), 20% lower than in Q1 2017. Last year included new license revenue of 1 MUSD. ✓ BIP sales increased by 157% - ten consecutive quarters of increasing BIP sales (rolling twelve-month figures) ✓ License revenues from BD, down by 5 MSEK
Slide 3: Health care-associated infections
3 Health care-associated infections HAI frequency 1 in every 10 patients affected by health care-associated infections worldwide In Sweden, health care-associated infections result in approximately 1,500 patient deaths every year. Source: WHO/HIS/SDS/2016.10
Slide 4: Media and public attention
Media and public attention svt NYHETER Nyheter © Spot SvTPlay ear 1 STOCKHOLM huset Huddinge Fot:TT Resistenta tarmbakterier sprids ‘Spridningen av resistenta tarmbakterier av typ VRE sprids fran sjukhus tillsjukhus i landet, enligt Dagens Nyheter som rapporterar om ett omfattande utbrott pa Karolin
Slide 5: Spread of resistant bacteria between hospitals
5 Spread of resistant bacteria between hospitals Sweden April 19, 2018 Source: Folkhälsomyndigheten/sida/artikel.aspx?artikel=6937628,
Slide 6: More than 150 patients identified with VRE since Dec-17 outbreak
6 From the break out in Dec-17, more than 150 patients indentified with VRE Source: Folhälsomyndigheten
Slide 7: The role of infection prevention and control
7 The role of infection prevention and control WHO: Every infection prevented is an antibiotic treatment avoided Source: www.who.int/campaigns/world-antibiotic-awareness-week/
Slide 8: Market update
8 Market update Europe • Breakthrough in Swedish tenders • New distributor for BeNeLux • Focus on adding new markets MEA CHINA • Major deliveries • Sales increased by more than 40% • Market activities ongoing at high • Strong development across the region intensity INDIA LATIN AMERICA • Deliveries o
Slide 9: Licensing business
9 Licensing business BD (C.R. Bard) • Successful partnership since 1995 • Bactiguard coated Foley catheters for the US, Japan and UK/Ireland • Generating stable annual revenues Vigilenz Medical Devices • Bactiguard coated orthopaedic trauma implants for the ASEAN markets • Aiming for CE mark in firs
Slide 10: Smartwise license agreement
10 Smartwise license agreement New therapeutic application ✓ Advanced Bactiguard-coated vascular injection catheters aimed at delivering high dose, locally targeted therapies to damaged tissue, in remote and critical areas of the body ✓ Coating reduces risk of infections and thrombosis in critically
Slide 11: Development in revenues from BIP products
Development in revenues from BIP products 11 Supplied products • Ten consecutive quarters of growth, based on rolling 12 months. • 21% CAGR in this time period.
Slide 12: Delivered products
Delivered products 12 Supplied products • Revenues from BIP-products of MSEK 7.3 (2.8) in Q1, related to 155 000 (48 000) units. • BIP revenue growth of 157% in Q1 • For the full year 2017, 502 000 units were delivered, generating revenues of MSEK 21.8
Slide 13: Financial highlights
13 Financial highlights Highlights First quarter (Jan-Mar 2018) • Revenues of MSEK 33.0 (41.0), decrease of 20%, mainly explained by no new license revenues in Q1 2018. • EBITDA of MSEK 1.8 (13.4), 6% EBITDA-margin
Slide 14: Revenue streams
14 Revenue streams Two revenue streams in the income statement License BIP portfolio BD (sales since 1995), Vigilenz BIP Foley BIP ETT BIP CVC and Smartwise 1 2 License BIP revenue From a product perspective Bactiguard has two lines of business; Licenses and the BIP portfolio, acknowledged in the ac
Slide 15: Revenue distribution
15 Revenue distribution Income distribution Jan-Mar Jan-Mar Full year MSEK 2018 2017 2017 License revenues 22,0 27,4 104,3 New license revenues 0,0 8,8 21,4 Sales of BIP products 7,3 2,8 21,8 Other revenues 3,7 2,0 6,2 Total Revenues 33,0 41,0 153,6
Slide 16: Financial flexibility and strength
16 Financial flexibility and strength Financial position • Equity ratio of 61 % • Net debt of MSEK 166.0 • Cash position of MSEK 6.0. Out of granted overdraft facility of MSEK 30, MSEK 8.4 was utilized 31 March 2018 Loans • Three-year MSEK 180 credit facility at Skandinaviska Enskilda Banken (SEB) r
Slide 17: Financial targets
17 Financial targets • Average sales growth of 20% per annum for a 5-year period, with 2015 as the base year – starting point MSEK 118.5 • EBITDA margin of at least 30% at the end of the 5-year period (by 2020) • Equity ratio of at least 30% • Over time uphold a dividend policy of 30-50% of net prof
Slide 18: Concluding remarks
18 Concluding remarks ✓ Revenues lower than last year ✓ Ten consecutive quarters of increasing BIP sales Strong development in China, India and the Middle East Swedish sales growing as tenders go live, Stockholm and Skåne ✓ Lower license revenues Lower revenues from Bard in the first quarter Prepari
Slide 19: Our vision
19 OUR VISION Eliminate healthcare associated infections to 1. save lives 2. reduce cost and 3. limit antimicrobial resistance, through preventive standards of care..
Slide 20: More information is available at www.bactiguard.se
20 More information is available at www.bactiguard.se For questions and additional information, please contact: Christian Kinch, CEO Phone +46 8 440 58 80 christian.kinch@bactiguard.se @ChristianKinch Cecilia Edström, CFO Phone +46 72-226 23 28 cecilia.edstrom@bactiguard.se @EdstromCecilia